Healthcare Industry News: Acculis
News Release - January 31, 2011
Microsulis Medical Limited Receives Health Canada Approval of the Accu2i Percutaneous Microwave Tissue Ablation Device
Device Provides Quick, Precise Coagulation of Unwanted Tissue MassesDENMEAD, England--(Healthcare Sales & Marketing Network)-- Microsulis Medical Limited, the leading company in microwave technology for medical devices, today announced that it has received approval from Health Canada for the Acculis Accu2i percutaneous microwave tissue ablation (pMTA) system for the coagulation of soft tissue during surgical procedures. The system has already been in use in Europe and the United States treating liver and lung tumors via a small 1.8 mm needle puncture of the skin. This groundbreaking treatment allows physicians to apply precise microwave energy to remove unwanted tissue masses whilst avoiding the risks associated with longer, more invasive surgical interventions.
The Accu2i pMTA system is now cleared in Europe, the United States, and Canada and it delivers 2.45 GHz of power to coagulate unwanted tissue masses. The design consists of a 1.8 mm diameter closed water cooled needle that allows physicians to coagulate large tissue volumes in minutes. The system is unique in that it uses specialized patented microwave antenna designs that achieve the very high levels of microwave energy deposition into tissue needed to quickly and effectively coagulate unwanted areas of soft tissue.
“The Health Canada approval builds on the momentum we experienced in 2010 with the CE mark and FDA clearance of the Accu2i pMTA system,” said Stuart McIntyre, CEO of Microsulis Medical Limited. “We are pleased to have received this approval from Health Canada for the pMTA system so physicians can begin to offer this game changing treatment option for patients in Canada.”
For more information about the Acculis Accu2i pMTA system, visit www.Acculis.com.
About Microsulis Medical Limited
Founded in 1997, Microsulis Medical Ltd is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic devices. The company was initially formed following research collaboration between Chemring and the University of Bath in 1993. The company leads the field in microwave technology for endometrial ablation, tumor ablation, and venous occlusion. Part of MML, Acculis specialises in devices for oncology applications. For more information on Microsulis Medical Limited please visit www.microsulis.com.
Source: Microsulis Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
